A non-profit and independent research entity dedicated to clinical studies, ethical standards, and patient-centered outcomes.
The Institute for Cannabinoid Research (ICR) is an interdisciplinary group that unites researchers, clinicians, and scientists from across the globe with a shared goal of advancing medical solutions.
The ICR's mission consists of three key objectives: (1) to encourage research into cannabinoids; (2) to facilitate the sharing of scientific knowledge and diverse perspectives on Cannabis, cannabinoids, and endocannabinoids by hosting scientific conferences; and (3) to act as a dependable resource for information on the chemistry, pharmacology, therapeutic applications, toxicology, and the behavioral, psychological, and social impacts of Cannabis and its components and terpenes, as well as synthetic and endogenous substances that engage with cannabinoid receptors or target other elements of the endocannabinoid system.
The ICR is a non-political, secular organization committed to unbiased scientific inquiry across all areas of cannabinoid and terpene research—ranging from biochemical, chemical, and physiological investigations of the endocannabinoid system to studies on the misuse potential of non-medical Cannabis. Beyond offering impartial information about Cannabis and cannabinoids and terpeneoids, the ICR's primary function is to create an open space where researchers can convene and exchange ideas about their work.
To foster international collaboration and advance scientific understanding of cannabinoids and terpenoids and the Endocannabinoid System.
Research, development, education, consulting, and public awareness initiatives.
ICR is in close connection for further education and guidance with globally recognized experts in biochemistry, molecular biology, neurotoxicology, physiology, cannabinoid and terpenoid pharmacology, oncology and translational medicine.
ICR extends its scientific data and logic thanks to the respectful gratitude to the pioneers Sean Munro (Molecular Biology, Cambridge, UK), Tom I. Bonner (National Institutes of Health NIH, US), Mauro Maccarrone (University of L'Aquila, Italy), Vincenzo Di Marzo (Université Laval, Canada), Roger Pertwee (University of Aberdeen, UK), Dale Deutsch (Professor Emeritus, Stony Brook University) and Allyn Howlett (Wake Forest School of Medicine, Winston-Salem).
The institute's research spans a wide range of scientific and clinical domains:
Research activities aim for hypothesis frameworks, reviews, research articles, randomized controlled trials, laboratory and animal studies, observational studies. These approaches seek to better understand the therapeutic potential and safety of cannabinoids and terpenes.
ICR along with affiliated clinics offers complementary cannabinoid-based therapy protocols for individuals with chronic medical conditions, including cancer, persistent pain, rheumatic disorders, and neurological diseases. We also support individuals without a formal diagnosis who seek preventive or wellness-oriented cannabinoid guidance for stress, sleep, pain, or seasonal health issues.
Our approach integrates conventional medicine with scientifically grounded cannabinoid interventions.
For more information please contact the ICR for:
Dr. Erhan Yarar – Translational medicine expert; Chief Clinician in Differential Diagnosis at the Institute for Cannabinoid Research, Netherlands. Emeritus Member of the International Cannabinoid Research Society, Winston-Salem, NC, USA; Member of the American Society for Biochemistry and Molecular Biology, USA
Dr. Mahir Yıldırım – Recognized pioneer in advanced cancer treatments, particularly as a leading practitioner of Isolated Regional Chemotherapy (IBK) and Chemosaturation (Delcath Systems); recognized for pioneering specialized, minimally invasive techniques for treating liver tumors and metastatic cancers.
Dr. Takashi Nakamura – Recognized expert on advanced glycation end products, Asai Germanium Research Institute, Japan
Dr. Stefano Fais – Anti-Tumour Drugs Section, Department of Therapeutic Research and Medicines Evaluation, National Institute of Health, Italy
Dr. Isaac Eliaz – Pioneer in the field of integrative medicine with a focus on cancer, immune health, detoxification and mind-body medicine; a Gal-3 expert and inventor of the Gal-3 inhibitor, USA
Monthly webinars with expert speakers on current cannabis research topics.
September 2026The Institute for Cannabinoid Research is a scientific organization comprised of active researchers working in the fields of endogenous, plant-derived, and synthetic cannabinoids, as well as related bioactive lipids. Become a member of the ICR to remain connected with the global cannabinoid research community.
Membership benefits include access to exclusive members-only content and discussion forums, as well as for webinars on cannabinoids and terpenoids.
Ph.D. or M.D. degree holders committed to cannabinoid research.
$200
Scientist with 10+ years' experience and retired.
$0
Students enrolled in related disciplines.
$0
Individuals with doctoral degree in postdoctoral position.
$80
Trainees with Bachelor's or Master's degree.
$50
Degree holders involved in cannabinoid research.
$200
Individuals or organizations.
$250
Attn: Dr. Erhan Yarar
Institute for Cannabinoid Research (ICR)
Einsteinlaan 28, 2289 CC Rijswijk
Netherlands
+44 7707 365285
info@icrinstitute.nl